Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

20.31 (USD) • At close January 3, 2025
Bedrijfsnaam Kiniksa Pharmaceuticals, Ltd.
Symbool KNSA
Munteenheid USD
Prijs 20.31
Beurswaarde 1,466,413,826
Dividendpercentage 0%
52-weken bereik 16.56 - 28.15
Industrie Biotechnology
Sector Healthcare
CEO Mr. Sanj K. Patel
Website https://www.kiniksa.com

An error occurred while fetching data.

Over Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a

Vergelijkbare Aandelen

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

1.02 USD

Pharvaris N.V. logo

Pharvaris N.V.

PHVS

18.53 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

1.525 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

9.62 USD

Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD

0.47 USD

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

1.55 USD

Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

4.66 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)